Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive Investors the Massachusetts-based company has landed its second major contract with an unnamed, multi-billion dollar pharmaceutical company to manufacture a candidate protein drug.
Schumacher says the deal utilizes Pressure’s BaroFold platform, which uses high pressure to modify protein drug samples, unfolding and refolding peptides, benefiting patients.
Price: $3.24
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical...
Industry & services
Industry & services
Prev article
